Factor XIII B CRISPR Activation Plasmid (h): sc-403574-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Factor XIII B CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Factor XIII B CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Factor XIII B CRISPR Activation Plasmid (h) and Factor XIII B CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the F13B transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Factor XIII B Antibody (GMA-033): sc-65957
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Factor XIII B CRISPR Activation Plasmid (h) | sc-403574-ACT | 20 µg | $397.00 |
F13B encodes the B subunit of coagulation factor XIII, a plasma transglutaminase complex component that circulates as an A2B2 heterotetramer and stabilizes the catalytic A subunit in the bloodstream. Upon thrombin activation and calcium binding, factor XIIIa crosslinks fibrin and other matrix proteins, strengthening clot architecture and increasing resistance to fibrinolysis. Through these extracellular matrix–stabilizing reactions, Factor XIII B contributes to hemostasis and wound repair–associated remodeling processes. Altered FXIII subunit balance and reduced FXIII activity are linked to bleeding phenotypes and abnormal clot stability, making F13B a relevant target for mechanistic studies in coagulation biology.
Factor XIII B CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous F13B expression without altering the underlying DNA sequence.
Factor XIII B CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the F13B locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the F13B transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Factor XIII B expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native F13B locus and enabling the study of Factor XIII B-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Factor XIII B pathway restoration in tumor cells with silenced or reduced F13B expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.